Cerep and Servier Establish new Collaboration Agreement for Drug Discovery and Lead Optimization
News Jun 26, 2009
Cerep has announced the signature with Servier of a 3-year collaboration agreement for the discovery and optimization of new drugs. The terms of the agreement provide that Servier will identify targets of interest and will transfer to Cerep its collection of compounds.
Cerep will be responsible for the development and validation of the corresponding pharmacological assays and will run high throughput screenings on Servier library.
As part of this agreement, Cerep will also profile hit compounds identified during the high throughput screening campaigns as well as the drug candidates optimized for the selected target. Screening and profiling data will be made available in real time through the secured web access system Data OnLine developed by Cerep.
In addition, Servier will have access to BioPrint® services for an improved interpretation of in vitro data and for a better selection of drug candidates with less potential side effects and optimized safety profile.
Financial terms of the agreement are undisclosed; they include a monthly payment during the 3 years of the collaboration.
Thierry Jean, Chairman and CEO of Cerep, commented: "Servier is an historical partner of Cerep and we have continuously entertained excellent relationships. We are particularly happy to sign a new collaboration which illustrates the high level of confidence and respect shared by the two companies."
Emmanuel Canet, President of Research and Development of Servier, declared: "With this agreement, Servier takes a new step in its contribution to medical progress and therapeutic innovation and confirms its commitment to collaborate with innovative biotech and research companies in France."
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE